Sequential treatment of bisulfate-converted DNA was used to study methylation of promoter areas of SEPT9, HLTF, ALX4 and CDH1 genes. Methylation profiles were evaluated by comparing bioptical findings on colorectal cancer (n=55) and morphologically intact areas of the large bowel (n=71). Significant differences between groups were established for SEPT9, HLTF and ALX4 genes (p < or = 10(-9)) in evaluating medium-rate methylation of CpG. Diagnostic sensitivity (Se) peaked for SEPT9 (78 +/- 7%); specificity--(86 +/- 4%) (Sp). On site CpG (position "+14"), similar findings were reported: Se=81 +/- 6%, Sp=77 +/- 5%. Therefore, CpG(14)SEPT9 may be used as a separate marker. As a result of the use of HLTF as marker on all 23 sites, Se was 67 +/- 6% and Sp--87 +/- 3%; ALX4 diagnostic sensitivity--59 +/- 6%. Specificity level was similar to those of the other genes (88 +/- 3%). Despite the role of CDH1 gene in colorectal cancer, the group-to-group differences in methylation rates were minimal. Such values of Se and Sp as 54 +/- 6% and 67 +/- 5%, respectively, could not support methylation of the CDH1 promoter area for diagnostic purposes. Therefore, combined evaluation of SEPT9, HLTF and ALX4 genes offered more advantage as far as diagnosis is concerned. Hypermethylation in two of the three genes was assumed as a criterion for diagnosis. Under such conditions, diagnostic sensitivity was 81 +/- 7% (Sp=93 +/- 3%). With such high values, the criterion has a potential of being instrumental in working out diagnostic tests for colorectal cancer.

Download full-text PDF

Source

Publication Analysis

Top Keywords

sept9 hltf
16
hltf alx4
16
alx4 genes
12
colorectal cancer
12
+/-
12
diagnostic sensitivity
8
genes
6
diagnostic
6
sept9
5
hltf
5

Similar Publications

Background & Objective: olorectal Cancer (CRC) is the third most common cancer after prostate (breast in women) and lung cancer; it is also the third cause of cancer deaths reported in both men and women in 2020. Currently, the most commonly used diagnostic tools for CRC are colonoscopy, serological methods, and other imaging techniques. Despite the benefits and abilities of these methods, each of them has disadvantages that reduce its functionality and acceptance.

View Article and Find Full Text PDF

DNA methylation based biomarkers in colorectal cancer: A systematic review.

Biochim Biophys Acta

August 2016

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands. Electronic address:

Since genetic and epigenetic alterations influence the development of colorectal cancer (CRC), huge potential lies in the use of DNA methylation as biomarkers to improve the current diagnosis, screening, prognosis and treatment prediction. Here we performed a systematic review on DNA methylation-based biomarkers published in CRC, and discussed the current state of findings and future challenges. Based on the findings, we then provide a perspective on future studies.

View Article and Find Full Text PDF

Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review.

Colorectal Dis

June 2016

Department of Gastrointestinal Surgery and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.

Aim: Improved methods for early detection of colorectal cancer (CRC) are essential for increasing survival. Hypermethylated DNA in blood or stool has been proposed as a biomarker for CRC. Biochemical methods have improved in recent years, and several hypermethylated genes that are sensitive and specific for CRC have been proposed.

View Article and Find Full Text PDF

Objectives: Colorectal cancer is the third most common cancer and a major cause of cancer-related deaths. Early detection of colonic lesions can reduce the incidence and mortality of colorectal cancer. Colonoscopy is the screening test for colorectal cancer with the highest efficacy, but its acceptance in the general public is rather low.

View Article and Find Full Text PDF

Sequential treatment of bisulfate-converted DNA was used to study methylation of promoter areas of SEPT9, HLTF, ALX4 and CDH1 genes. Methylation profiles were evaluated by comparing bioptical findings on colorectal cancer (n=55) and morphologically intact areas of the large bowel (n=71). Significant differences between groups were established for SEPT9, HLTF and ALX4 genes (p < or = 10(-9)) in evaluating medium-rate methylation of CpG.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!